-
Notable Analyst Rating Changes 8/28: (HBAN) (MDCO) (ARCC) Upgraded; (MTGE) (TDC) (BWA) Downgraded
-
Medicines (MDCO) Loss of Exclusivity on Angiomax Seen as 'Anticipated Event' - RBC
-
Medicines' (MDCO) Angiomax Win vs Mylan Helps but Hospira Overhang Remains, Says RBC
-
Notable Analyst Rating Changes 04/17: (SCTY) (NFLX) (GOGO) Upgraded; (HBAN) (SO) (MDCO) Downgraded
-
Medicines (MDCO) Investors Overreacting, Says RBC
-
Notable 52-Week Highs and Lows of the Day 01/08: (PERI) (NCT) (CELG) High; (ALLT) (AU) Low
-
Notable Analyst Rating Changes 10/07: RBN, CRM, VIA-B, WFR Upgraded; COST, MDCO, CTL, DPS Downgraded
-
RBC Capital Downgrades Medicines Co. (MDCO) to Sector Perform
-
RBC Capital Upgrades The Medicines Co. (MDCO) to Outperform
-
Unusual 11 Mid-Day Movers 9/2: KV.A, PAY, MDCO, MDZ Higher; DHT, SEAC, SVA, SYNO Lower